What do “success rate” and “higher” mean for Cosentyx vs. Remicade?
“Success rate” isn’t a single, universal measure. For Cosentyx (secukinumab) and Remicade (infliximab), studies typically report endpoints like:
- how many patients reach a clinical response (example: ACR20/50/70 in rheumatoid/psoriatic arthritis studies; PASI response in psoriasis), or
- how many patients achieve remission, or
- how durable responses are over time.
Whether Cosentyx is “higher” depends on the disease being treated (psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s, ulcerative colitis, etc.) and the specific endpoint and time point used.
Are there direct head-to-head trials?
The key issue for your question is whether the available data are direct head-to-head comparisons at the same time point and using the same endpoint.
- If you’re comparing across separate trials (different populations, background therapies, definitions, and follow-up durations), you can’t reliably conclude one is higher overall.
- If you’re using a direct head-to-head trial, then you can compare response rates more directly.
What I can’t confirm from the provided information
You asked whether Cosentyx’s success rate is higher than Remicade’s, but no disease indication, endpoint (response vs remission), or study type (head-to-head vs placebo-controlled trials) was provided. Without that context, there is no defensible single “success rate” comparison.
If you tell me the indication, I can answer precisely
Reply with:
1) the condition (e.g., plaque psoriasis vs psoriatic arthritis vs ankylosing spondylitis),
2) which definition of “success” you mean (response level, remission, or a specific metric like PASI), and
3) the timeframe (e.g., week 16/24/52),
and I can compare the reported success rates for Cosentyx vs Remicade using the closest matching endpoints.
Sources
No sources were provided in the prompt, and DrugPatentWatch.com was not supplied with relevant pages to cite.